Related Experiment Video
Updated: Jul 6, 2026

Characterizing DNA Repair Processes at Transient and Long-lasting Double-strand DNA Breaks by Immunofluorescence Microscopy
Published on: June 8, 2018
The BRCA1-A complex restricts replication fork reversal-dependent DNA repair in ATM deficient cells
Arindam Datta1, Jessica Jackson2, Yaroslav I Morozov1
1Department of Cancer Biology, Penn Center for Genome Integrity, Basser Center for BRCA, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstract:
Ataxia Telangiectasia Mutated (ATM) kinase deficiency results in cancer susceptibility and drug hypersensitivity. Deficiency in either the BRCA1 interacting A complex or XRCC4/Ligase 4 confers resistance to Topoisomerase I or PARP1 inhibitors in ATM-deficient cells. This suggests that BRCA1-A directs toxicity to fork-damaging agents in ATM mutated cells via illegitimate end-joining. Here, we show that ATM inhibition triggers combined SUMO and ubiquitin mediated BRCA1-A damaged fork recognition to restrict end-resection and cause Topoisomerase I inhibitor hypersensitivity. BRCA1-A deficient cells display elevated chromatin accessibility and nuclease activity at damaged forks, coupled with restored resection and drug resistance. Electron microscopy evidence demonstrates that ATM inhibition prevents replication fork reversal, which is restored by BRCA1-A loss to generate substrates for end resection. These findings reveal that BRCA1-A enforces a restrictive chromatin state to suppress the genesis of resection substrates, implicating fork reversal as a key determinant of chemotherapy response in ATM deficient cells.
Insights
Ataxia Telangiectasia Mutated (ATM) kinase deficiency causes cancer and drug sensitivity. BRCA1-A complex loss in ATM-deficient cells restores drug resistance by enabling DNA end resection at damaged forks.
Area of Science:
- DNA repair mechanisms
- Cancer biology
- Genetics
Background:
- Ataxia Telangiectasia Mutated (ATM) kinase deficiency leads to cancer and drug hypersensitivity.
- BRCA1-interacting protein A (BRCA1-A) complex or XRCC4/Ligase 4 deficiency confers resistance to Topoisomerase I or PARP1 inhibitors in ATM-deficient cells.
- BRCA1-A complex may direct toxicity to DNA damaging agents in ATM-mutated cells via illegitimate end-joining.
Purpose of the Study:
- To investigate the role of ATM inhibition in DNA damage response.
- To elucidate the mechanism by which BRCA1-A complex influences drug sensitivity in ATM-deficient cells.
- To identify key factors determining chemotherapy response in ATM-deficient cancers.
Main Methods:
- Cellular assays to assess DNA damage recognition and repair.
- SUMOylation and ubiquitination assays.
- Chromatin accessibility and nuclease activity measurements.
- Electron microscopy to visualize replication fork dynamics.
- Drug sensitivity assays with Topoisomerase I inhibitors.
Main Results:
- ATM inhibition triggers SUMO and ubiquitin-mediated BRCA1-A recognition of damaged forks, restricting end-resection and causing Topoisomerase I inhibitor hypersensitivity.
- BRCA1-A deficient cells exhibit increased chromatin accessibility and nuclease activity at damaged forks, restoring DNA end resection and drug resistance.
- ATM inhibition prevents replication fork reversal; loss of BRCA1-A restores fork reversal, generating substrates for end resection.
Conclusions:
- BRCA1-A enforces a restrictive chromatin state to prevent the formation of DNA end resection substrates.
- Replication fork reversal is a critical determinant of chemotherapy response in ATM-deficient cells.
- Targeting BRCA1-A or modulating fork reversal may offer therapeutic strategies for ATM-deficient cancers.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Restarting Stalled Replication Forks
Homologous Recombination
The DNA Replication Fork
The DNA Replication Fork

